Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K current report with the SEC on August 18, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia.
Amylyx Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia
- Announcement dated August 18, 2026, highlighting a potentially important clinical-development milestone
- Full efficacy and safety findings available in Exhibit 99.1, relevant to regulatory and commercial outlook
Item 8.01 · Other Events
- Phase 3 LUCIDITY met its FDA-agreed primary endpoint, reducing combined Level 2 and Level 3 hypoglycemic events 55% versus placebo
- Highly significant efficacy, with p=0.000003 and all secondary endpoints achieved across SMBG, CGM, and adjudicated Level 3 events
- Avexitide generally well tolerated, with no treatment-related serious adverse events and no body-weight changes over 16 weeks
- NDA submission planned by end of 2026, supported by FDA Breakthrough Therapy Designation
- 32-week open-label extension and expanded access program remain ongoing, with commercialization still subject to FDA approval
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 LUCIDITY met its primary endpoint, reducing combined Level 2 and Level 3 hypoglycemic events 55% versus placebo through Week 16
- Highly significant efficacy, with p=0.000003 and all secondary endpoints met across SMBG, CGM, and independently adjudicated Level 3 events
- Favorable safety profile, with no serious adverse events related to avexitide and no body-weight changes over 16 weeks
- Amylyx plans an FDA NDA submission by year-end 2026, supporting potential commercial launch in 2027 if approved
- Breakthrough Therapy and Orphan Drug designations could support regulatory development for the first approved PBH treatment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amylyx Pharmaceuticals, Inc. 8-K filings
Get the next AMLX 8-K as it lands
Follow AMLX for push alerts, or ask the research agent what this filing means.